• CARR of A$30.8M; ARR Run Rate of A$24.4M at 31 March 2025
• Sales orders of A$5.1M (TCV) in Q3 FY25; A$21.3M for 9 months to 31 March 2025
• Cash receipts of A$11.4M, up 28.4% on PCP

Mach7 Technologies Ltd, a company specialising in innovative medical imaging software solutions, has provided a business update and quarterly cashflow report for the quarter ended 31 March 2025. The company reported Contracted Annual Recurring Revenue (CARR) of A$30.8M, a decrease of A$0.7M compared to 31 December 2024 in constant currency. The company's Annual Recurring Revenue (ARR) run rate was A$24.4M at 31 March 2025. Sales orders for the third quarter of FY25 totaled A$5.1M (TCV), with the majority of sales orders received for ARR-type sales. Cash receipts from customers in Q3 FY25 were A$11.4M, up 28.4% compared to Q3 FY24 and up 18.3% on Q2 FY25. Mach7 was operating cashflow positive in Q3 FY25 for a second consecutive quarter with operating cash inflows of A$2.6M. The company's financial position remains strong with no debt and A$24.9M cash on hand at 31 March 2025. During the quarter, Mach7 commenced an on-market share buy-back program, acquiring approximately 1.9M shares at a cost of A$0.7M. The company also announced the appointment of Teri Thomas as Managing Director & CEO, commencing on 1 July 2025, with current CEO Mike Lampron stepping down on 30 June 2025.

Mach7 reaffirms its FY25 guidance for 15-25% growth in CARR and revenue on PCP and for OPEX growth to be less than revenue growth.

Looking ahead, the company expects to see continued demand and volume growth from both new and existing customers across North America, APAC and the Middle East. Q3 FY25 cost out initiatives are expected to result in A$2M-3M in annualised savings.